Grace Therapeutics (GRCE) Competitors $3.13 +0.11 (+3.64%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. SLN, ENTA, IPHA, ACOG, DERM, SPRO, NVCT, CGEN, LFVN, and DMACShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Silence Therapeutics (SLN), Enanta Pharmaceuticals (ENTA), Innate Pharma (IPHA), Alpha Cognition (ACOG), Journey Medical (DERM), Spero Therapeutics (SPRO), Nuvectis Pharma (NVCT), Compugen (CGEN), Lifevantage (LFVN), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Silence Therapeutics Enanta Pharmaceuticals Innate Pharma Alpha Cognition Journey Medical Spero Therapeutics Nuvectis Pharma Compugen Lifevantage DiaMedica Therapeutics Silence Therapeutics (NASDAQ:SLN) and Grace Therapeutics (NASDAQ:GRCE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Which has stronger valuation and earnings, SLN or GRCE? Grace Therapeutics has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics$43.26MN/A-$45.31M-$1.50-3.69Grace TherapeuticsN/AN/A-$9.57M-$0.89-3.52 Do analysts recommend SLN or GRCE? Silence Therapeutics presently has a consensus target price of $33.83, suggesting a potential upside of 510.71%. Grace Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 283.39%. Given Silence Therapeutics' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLN or GRCE more profitable? Grace Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -260.55%. Grace Therapeutics' return on equity of -19.45% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence Therapeutics-260.55% -56.17% -33.96% Grace Therapeutics N/A -19.45%-16.99% Do institutionals & insiders have more ownership in SLN or GRCE? 98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 4.1% of Silence Therapeutics shares are held by insiders. Comparatively, 13.5% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor SLN or GRCE? In the previous week, Silence Therapeutics had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for Grace Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Grace Therapeutics'average media sentiment score. Company Overall Sentiment Silence Therapeutics Neutral Grace Therapeutics Neutral Which has more risk and volatility, SLN or GRCE? Silence Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. SummaryGrace Therapeutics beats Silence Therapeutics on 8 of the 14 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.28M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-3.5221.5627.4320.23Price / SalesN/A281.76422.11118.64Price / CashN/A42.7336.8958.07Price / Book0.647.518.045.67Net Income-$9.57M-$55.05M$3.18B$249.13M7 Day Performance5.39%4.61%2.89%3.28%1 Month Performance5.74%4.72%3.70%5.56%1 Year PerformanceN/A5.92%36.15%21.12% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics1.7875 of 5 stars$3.13+3.6%$12.00+283.4%N/A$43.28MN/A-3.52N/ASLNSilence Therapeutics1.9683 of 5 stars$5.54-2.6%$33.83+510.7%-69.2%$170.30M$27.70M-3.69100ENTAEnanta Pharmaceuticals4.0942 of 5 stars$7.89-1.0%$18.00+128.1%-40.0%$168.69M$67.64M-1.74160Positive NewsIPHAInnate Pharma2.5565 of 5 stars$1.82+0.1%$11.00+504.1%-15.3%$167.85M$12.62M0.00220Positive NewsGap DownACOGAlpha Cognition1.7696 of 5 stars$10.47-2.1%$20.00+91.0%N/A$167.73MN/A-8.72N/ANews CoverageDERMJourney Medical1.6667 of 5 stars$7.10+0.9%$9.50+33.8%+37.9%$165.43M$56.13M-18.2190SPROSpero Therapeutics3.9182 of 5 stars$2.91+0.3%$5.00+71.8%+119.6%$162.70M$47.98M-2.27150NVCTNuvectis Pharma2.66 of 5 stars$7.70+2.4%$17.00+120.8%+24.2%$160.85MN/A-6.818CGENCompugen1.5762 of 5 stars$1.78+2.3%$4.00+124.7%+6.6%$158.84M$27.59M-11.1370LFVNLifevantage4.1673 of 5 stars$12.53-6.5%$30.50+143.5%+109.1%$157.69M$200.16M18.15260News CoverageDMACDiaMedica Therapeutics0.9092 of 5 stars$3.65+2.2%$8.00+119.2%+26.3%$156.51MN/A-5.7020 Related Companies and Tools Related Companies Silence Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Innate Pharma Alternatives Alpha Cognition Alternatives Journey Medical Alternatives Spero Therapeutics Alternatives Nuvectis Pharma Alternatives Compugen Alternatives Lifevantage Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
